about
Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement SystemA call for a moratorium on the .health generic top-level domain: preventing the commercialization and exclusive control of online health informationPromoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance.Corporate social responsibility to improve access to medicines: the case of Brazil.Civil society participation in the health system: the case of Brazil's Health CouncilsWhy the MDGs need good governance in pharmaceutical systems to promote global health.Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers.Framing access to medicines in developing countries: an analysis of media coverage of Canada's Access to Medicines Regime.The role of supportive supervision on immunization program outcome - a randomized field trial from GeorgiaAchieving a dream: meeting policy goals related to improving drug accessCanada's Access to Medicines Regime: Promise or Failure of Humanitarian Effort?Corruption in the health care sector: A barrier to access of orthopaedic care and medical devices in UgandaHealth domains for sale: the need for global health Internet governance.An examination of pharmaceutical systems in severely disrupted countriesCanada's neglected tropical disease research network: who's in the core-who's on the periphery?Participatory health councils and good governance: healthy democracy in Brazil?The politics behind the implementation of the WTO Paragraph 6 Decision in Canada to increase global drug access.Policy versus practice: a community-based qualitative study of the realities of pharmacy services in Nunavut, Canada.The make or buy debate: considering the limitations of domestic production in Tanzania.Governance and pharmacovigilance in Brazil: a scoping reviewPrescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists."To patent or not to patent? the case of Novartis' cancer drug Glivec in India".Matching safety to access: global actors and pharmacogovernance in Kenya- a case study.The success rate of new drug development in clinical trials: Crohn's disease.Ensuring the future of health information online.Panel: Canada's law on global access to affordable medicines.No More Broken Promises: Challenges and Opportunities for Key Populations in Demanding More Transparency, Accountability, and Participation in the Global Response Against the HIV and AIDS Epidemic.How to achieve international action on falsified and substandard medicines.Finding flaws: the limitations of compulsory licensing for improving access to medicines--an international comparison.The Global Wicked Problem of Corruption and Its Risks for Access to HIV/AIDS Medicines
P50
Q28546974-B755D21E-7095-4179-8E09-2A86931BD599Q28655409-075DBD5A-1141-43BF-A4E2-2A06AB89C89BQ30376595-6E3AB4F1-F60F-4315-974F-2972BC18F1ADQ30378687-7D08EA04-407A-4B3E-8C6E-5AB27ACA2A67Q30380780-6C5E78AB-8731-4A7F-9B02-B52003E68015Q30392389-99DEA0FD-BE8A-4E52-A189-351796185A01Q30491589-CB6207CD-356F-45DB-AAE9-704C1F11502DQ30493324-6EFA3AB1-E780-4A11-9151-B202BFCAED1BQ33510446-B602B946-5ED9-4810-88D8-76933B89826AQ33643770-3C81B53B-3588-4AE4-8337-DD3EC33C8B30Q33701786-CC82CEC9-AD4F-4D5A-A067-6F089517E83CQ34255073-C38DF80A-8D70-44ED-B5E6-056A27871EB3Q34408443-3EF853E1-A2D2-4CA9-820E-2AED15CC1AC0Q34503013-C172038A-FE97-42A6-9B8B-66D6BD7630CBQ35068044-043532DF-34BF-49B0-A688-EBF84F6A2EE3Q35128049-652EB46E-FB99-4485-A850-232C4F04638EQ36072535-04B517CE-C0F5-458F-99E3-201DE0B3933CQ36076807-E5DD59C9-2838-4C9C-9D4F-EC217F02A9ADQ36146319-699DE5E6-BEC9-4768-AC96-E610266B5E86Q36560786-CECEB836-0B13-4548-A6B7-1251E301F4A4Q36596045-1B4516E0-E92B-4F56-9829-6BF36890E565Q37446290-4D6DBB91-4E98-4BE9-9981-A0114C61A57BQ37717536-5EDBEE6E-5CE5-44BD-A32B-592217ADEFC3Q39841108-4686C46F-6490-4751-BA90-E48B1C432914Q46112386-201E9F41-B8DA-41A1-BBEF-4A510E2A581DQ46319637-045BD901-EA78-4B00-AEC6-95766D02E1C6Q47107878-3BF878DB-7625-4E76-A2EF-CC0476DDDDC9Q53120792-E8DA15CB-22C5-4477-9A0E-4242DA278612Q53223320-4E5D118F-3443-4095-970A-1E3486603009Q57928403-48FB9B0B-0611-4066-B505-5ABA7C755EBE
P50
name
Jillian Clare Kohler
@ast
Jillian Clare Kohler
@en
Jillian Clare Kohler
@nl
type
label
Jillian Clare Kohler
@ast
Jillian Clare Kohler
@en
Jillian Clare Kohler
@nl
prefLabel
Jillian Clare Kohler
@ast
Jillian Clare Kohler
@en
Jillian Clare Kohler
@nl